Click here to close now.

SYS-CON MEDIA Authors: Elizabeth White, Carmen Gonzalez, Pat Romanski, Liz McMillan, AppDynamics Blog

News Feed Item

Berg And The Parkinson's Institute And Clinical Center Announce Key Clinical Study Focused On Game-changing Innovations In Parkinson's Disease Biomarker Discovery

Third Phase of Collaboration Aims to Unravel Mysteries of Disease by Identifying Disease Markers and Potential New Drug Targets

FRAMINGHAM, Mass. and SUNNYVALE, Calif., Feb. 18, 2014 /PRNewswire/ -- Berg and the Parkinson's Institute and Clinical Center today announced the next phase in their ongoing partnership, focused on identifying potential biomarkers that may lead to breakthroughs in the research, diagnosis, and treatment of Parkinson's disease. Using Berg's Interrogative Biology™ platform to analyze multi-omic tissue samples (skin fibroblasts, blood, urine) supplied by the Parkinson's Institute, this collaboration will identify the differences between healthy and diseased tissues in an effort to unravel the mysteries of Parkinson's disease. Berg and the Parkinson's Institute together are the first teams to approach biomarker discovery by looking at proteomics, metabolomics, and lipidomics, in addition to clinical data, simultaneously in human patients and controls from the same cohort.   

The new clinical study launched at the Parkinson's Institute and Clinical Center will collect urine, blood, and other relevant tissue samples from people living with Parkinson's disease. These materials will be used to validate biomarker candidates identified previously from the collaboration. Most importantly, this will represent a first in merging patients' molecular and clinical information to develop profiles that will drive the development of biomarkers.

Berg is a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach. The Parkinson's Institute is America's only independent, non-profit organization that brings together world-class care, laboratory research, clinical research, and clinical trials for Parkinson's disease under one roof.

"This partnership harnesses the exceptional clinical expertise and superior research resources of the Parkinson's Institute, along with Berg's unique ability to integrate patient-specific molecular data with clinical and demographic information," said Niven R. Narain, Co-Founder, President and Chief Technology Officer of Berg. "This new and exciting phase of our collaboration has the potential to create a number of game-changing innovations to better diagnose and manage Parkinson's disease."

Parkinson's disease is a progressive movement-related disorder of the central nervous system. It is estimated that there are approximately one million Americans living with Parkinson's. Each year, 50,000 new cases are diagnosed, and this rate is expected to rise with the aging baby boomer population. A clear understanding of Parkinson's and its underlying pathophysiology continues to be elusive as a result of the disease's complexity and a lack of predictive capability among existing models.

The expectation for this partnership is that it will help lead to a greater understanding of Parkinson's disease and the development of new tools that can change its course.

"Through our collaboration with Berg, we hope to identify predictors for the disease and potential new drug targets. Armed with this information, we will be able to better diagnose and develop therapies that can treat and perhaps even halt the neurological damage caused by Parkinson's, " said Birgitt Schuele, M.D., Director of Gene Discovery and Stem Cell Modeling at the Parkinson's Institute. "This collaboration is very exciting. Our discoveries have the potential to change the way we think about and approach Parkinson's disease."

One fundamental and defining contribution of the Berg-Parkinson's Institute collaboration will be to provide hallmark insights into disease pathophysiology.

"With diseases like cancer and diabetes, we at least have a foundational map and understanding of their pathways. Our challenge with most central nervous system (CNS) diseases is that there is a gross lack of understanding of the molecular pathways and drivers of disease pathophysiology. The anchor points are just not as clear as they are with other disease states," said Paula P. Narain, CNS Disease Program Lead at Berg. "This collaboration will lead to insights into disease mechanisms that will provide a solid foundation for biomarker and therapeutic candidate discovery. Berg is confident that the combination of tissue samples and expertise from the Parkinson's Institute, together with their award-winning Interrogative Biology™ platform, will usher in a paradigm shift in Parkinson's disease."

To learn more about Parkinson's disease, please visit the Parkinson's Institute at ThePI.org. To learn more about Berg, please visit BergPharma.com.

About the Berg Interrogative Biology™ Platform
Berg's application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The Berg Interrogative Biology™ platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population.

About Berg                           
Berg, the namesake of Carl Berg, is a biopharmaceutical company and parent company to Berg Pharma, Berg Biosystems and Berg Diagnostics. Our research focus seeks to understand how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg is poised to realize its pursuit of a healthier tomorrow. For additional information, visit http://www.bergpharma.com/.

About the Parkinson's Institute and Clinical Center
Two and a half decades ago, a dedicated group of Parkinson's disease experts set out to create a better way to research and provide care for Parkinson's disease. We would go beyond your standard doctor-patient relationship. Patients would become partners in developing their care plans, improving their quality of life, and discovering new strategies to confront and manage their disease. Compassionate care would work hand in hand with cutting-edge research to seek answers, develop new therapies and treatments, and ultimately work toward a cure. Our result was the Parkinson's Institute and Clinical Center. Along the way, we have built something that's thoroughly unique. Our Institute is a place where people living with Parkinson's can both pursue their care and play an important role in research that will undoubtedly continue to change the landscape of Parkinson's science and medicine. We are America's only independent nonprofit organization combining world-class care, clinical research, and laboratory research for Parkinson's disease under one roof. By virtue of our design, we are uniquely equipped to provide the best care, accelerate promising science, and perhaps most important—integrate the two and everything in between. It's what we now call Our Virtuous Circle and people living with Parkinson's and their loved ones are at the center of all that we do.

Connect with the Parkinson's Institute: 
www.ThePI.org 
www.Facebook.com/PDpartner 
www.Twitter.com/PDpartner

Contact: Chris Wahlers, 212-880-5293, [email protected]

SOURCE Berg

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In today's digital world, change is the one constant. Disruptive innovations like cloud, mobility, social media, and the Internet of Things have reshaped the market and set new standards in customer expectations. To remain competitive, businesses must tap the potential of emerging technologies and markets through the rapid release of new products and services. However, the rigid and siloed structures of traditional IT platforms and processes are slowing them down – resulting in lengthy delivery ...
SYS-CON Events announced today that Vitria Technology, Inc. will exhibit at SYS-CON’s @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Vitria will showcase the company’s new IoT Analytics Platform through live demonstrations at booth #330. Vitria’s IoT Analytics Platform, fully integrated and powered by an operational intelligence engine, enables customers to rapidly build and operationalize advanced analytics to deliver timely business outcomes ...
Wearable technology was dominant at this year’s International Consumer Electronics Show (CES) , and MWC was no exception to this trend. New versions of favorites, such as the Samsung Gear (three new products were released: the Gear 2, the Gear 2 Neo and the Gear Fit), shared the limelight with new wearables like Pebble Time Steel (the new premium version of the company’s previously released smartwatch) and the LG Watch Urbane. The most dramatic difference at MWC was an emphasis on presenting we...
Are your applications getting in the way of your business strategy? It’s time to rethink your IT approach. In his session at 16th Cloud Expo, Madhukar Kumar, Vice President, Product Management at Liaison Technologies, will discuss a new data-centric approach to IT that allows your data, not applications, to inform business strategy. By moving away from an application-centric IT model where data integration and analysis are subservient to the constraints of applications, your organization will b...
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY., and the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MangoApps provides private all-in-one social intranets allowing workers to securely collaborate from anywhere in the world and from any device. Social, mobile, and eas...
WSM International has launched a DevOps services division that offers assessment, consulting and implementation to large enterprises and organizations with complex infrastructures. The concept of DevOps is to blend information technology (IT) software development with operations to optimize the computing infrastructure according to the specific needs of the organization. According to a recent press release from Gartner, "By 2016, DevOps will evolve from a niche strategy employed by large cloud ...
SYS-CON Events announced today that Solgenia will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY, and the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Solgenia is the global market leader in Cloud Collaboration and Cloud Infrastructure software solutions. Designed to “Bridge the Gap” between Personal and Professional S...
SYS-CON Events announced today that QTS Realty Trust, one of the nation’s largest and fastest-growing providers of data center facilities and cloud services and a leader in security and compliance, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. QTS Realty Trust, Inc. (NYSE: QTS) is a leading national provider of data center solutions and fully managed services, and a leader in security and compliance...
SYS-CON Events announced today that WSM International (WSM), the world’s leading cloud and server migration services provider, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. WSM is a solutions integrator with a core focus on cloud and server migration, transformation and DevOps services.
SYS-CON Events announced today that Liaison Technologies, a leading provider of data management and integration cloud services and solutions, has been named "Silver Sponsor" of SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York, NY. Liaison Technologies is a recognized market leader in providing cloud-enabled data integration and data management solutions to break down complex information barriers, enabling enterprises to make sm...
What’s inside the cloud? Hard work. Cloud operators know the world inside the datacenter is gritty. Vendor marketing speak and cloudwashing quickly melt in the heat of SLAs, uptime guarantees, and users who want it now. In his session at DevOps Summit, Hernan Alvarez, Chief Product Officer at Blue Box Group, will deliver an unvarnished look inside the world of cloud operators, from the perspective of someone who lives it. Attendees get a front-row look into the toolkits and processes that enabl...
Connected devices and the Internet of Things are getting significant momentum in 2014. In his session at Internet of @ThingsExpo, Jim Hunter, Chief Scientist & Technology Evangelist at Greenwave Systems, examined three key elements that together will drive mass adoption of the IoT before the end of 2015. The first element is the recent advent of robust open source protocols (like AllJoyn and WebRTC) that facilitate M2M communication. The second is broad availability of flexible, cost-effective ...
Sematext is a globally distributed organization that builds innovative Cloud and On Premises solutions for performance monitoring, alerting and anomaly detection (SPM), log management and analytics (Logsene), and search analytics (SSA). We also provide Search and Big Data consulting services and offer 24/7 production support for Solr and Elasticsearch.
SYS-CON Events announced today that Akana, formerly SOA Software, has been named “Bronze Sponsor” of SYS-CON's 16th International Cloud Expo® New York, which will take place June 9-11, 2015, at the Javits Center in New York City, NY. Akana’s comprehensive suite of API Management, API Security, Integrated SOA Governance, and Cloud Integration solutions helps businesses accelerate digital transformation by securely extending their reach across multiple channels – mobile, cloud and Internet of Thi...
The speed of software changes in growing and large scale rapid-paced DevOps environments presents a challenge for continuous testing. Many organizations struggle to get this right. Practices that work for small scale continuous testing may not be sufficient as the requirements grow. In his session at DevOps Summit, Marc Hornbeek, Sr. Solutions Architect of DevOps continuous test solutions at Spirent Communications, will explain the best practices of continuous testing at high scale, which is r...